1. Home
  2. SCSC vs MNKD Comparison

SCSC vs MNKD Comparison

Compare SCSC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ScanSource Inc.

SCSC

ScanSource Inc.

HOLD

Current Price

$53.09

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$4.14

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCSC
MNKD
Founded
1992
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
1997
2004

Fundamental Metrics

Financial Performance
Metric
SCSC
MNKD
Price
$53.09
$4.14
Analyst Decision
Hold
Buy
Analyst Count
1
8
Target Price
$43.00
$8.69
AVG Volume (30 Days)
203.8K
5.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.42
N/A
Revenue
$3,846,260,000.00
$348,966,000.00
Revenue This Year
$2.60
$35.81
Revenue Next Year
$4.01
$11.89
P/E Ratio
$22.09
N/A
Revenue Growth
7.79
22.23
52 Week Low
$33.76
$2.23
52 Week High
$53.46
$6.51

Technical Indicators

Market Signals
Indicator
SCSC
MNKD
Relative Strength Index (RSI) 70.03 56.60
Support Level $38.55 $3.77
Resistance Level N/A $4.29
Average True Range (ATR) 1.33 0.23
MACD 0.02 -0.02
Stochastic Oscillator 87.71 47.44

Price Performance

Historical Comparison
SCSC
MNKD

About SCSC ScanSource Inc.

ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: